Belkin Announces Mobile Charging Accessories That Are Made-to-Move and New Ways to Protect and Connect Devices
Belkin International at Exhibit Hall 3.2, stand #210
Belkin, a leading consumer electronics brand for over 40 years, today announced 11 new travel-ready products across its mobile charging category, as well as solutions to enable more flexible options to work while on the go. Designed in California at its in-house labs, the new announcements underscore Belkin innovation, quality and its commitment to building products consumers need. All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905171274/en/
Belkin announces new BoostCharge collection at IFA 2024 (Photo: Business Wire)
Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
Foldable Wireless Chargers with Qi2
BoostCharge Magnetic Foldable Charger
This folding stand design is compact and travel ready. Delivering 15W of fast wireless charging to iPhone and other Qi2 enabled devices, its powerful magnetic connection secures the device to charging stand and magnetically holds it vertically or horizontally for hands-free use. Use the elevated, customizable position to scroll or watch, and support the Standby Mode feature for iPhone users. It is available in two versions: standalone charges phone only; the 2-in-1 version charges phone and earbuds. 20W power supply and USB-C cable are included. Premium materials include soft touch phone pad, non-slip base and durable hinge construction.
Price: $44.99 / £39.99 / €44.99 to $69.99 / £59.99 / €69.99
Availability: Standalone version coming September 2024; 2-in-1 version available now at belkin.com and available from Autumn 2024 in select retailers worldwide.
BoostCharge 3-in-1 Magnetic Foldable Charger
Charge all your essentials with this foldable 3-in-1. Both portable and with customizable charging angles, it delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. If used as a pad, keep it flat. If a stand is preferred, the pad lifts easily and holds steady. Simply fold it down for safe transport when it’s time to pack it away.
Price: $99.99 / £99.99 / €99.99
Availability: Available now at belkin.com and select retailers worldwide.
BoostCharge Pro Magnetic Wireless Travel Pad
A traveller’s best friend. Available in both 2-in-1 and 3-in-1 versions, use it as a pad or fold up into a stand. It delivers 15W of fast wireless charging to iPhone or Qi2 enabled device, 5W to Apple Watch and 5W for earbuds. Qi2 magnetic technology means the phone is held secure, optimizing energy usage and safeguarding the device's battery life.
Price: $119.00 / £109.00 / €119.00 to $129.99 / £119.99 / €129.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.
High-capacityPower Banks
BoostCharge Power Bank 10K w/ Integrated Cable
This compact 10K power bank makes charging easy. With integrated PD PPS, charge a USB-C smartphone, earbuds or tablet. It provides the option to split the power and charge multiple devices at once. Available in Black, Blue and Pink and White (MEA exclusive).
Price: $39.99 / £24.99 / €29.99
Availability: Coming Autumn 2024 to belkin.com and select retailers worldwide.
BoostCharge Pro 3-Port Laptop Power Bank 20K
This 65W power bank is built with a 20K battery capacity; enough to charge a laptop, MacBook or smartphone quickly and safely. Its full colour digital display shows battery status to easily monitor the remaining charge and manage power needs efficiently for all devices. Options for 65W PD via single USB-C connection or split the power across two USB-Cs and a USB-A, to charge 3 devices simultaneously.
Price: $89.99 / £79.99 / €89.99
Availability: Available now at belkin.com and belkin.com/uk, and coming soon to select retailers worldwide.
Cables Made More Responsibly
BoostCharge 2-in-1 USB-C and Lightning Cable
Charge existing and future devices with this 2-in-1 cable. MFi and USB-IF certified and tested to over 30,000 bends and over 10,000 plug-ins, this cable will deliver up to 60W of power to any USB-C or Lightning device. It features a built-in interchangeable Lightning connector for users to easily switch between their charging needs. A handy cable strap keeps things tidy and protects it from tangles. Exterior braiding is made of 100% post-consumer recycled polyester, certified by the Global Recycled Standard (GRS), cable head and internal jacket are made of 50% GRS-certified post-consumer recycled thermoplastic.
This is part of a rolling change to transition all our PVC and Braided PVC to PCR material.
Price: $24.99 / £19.99 / €24.99
Availability: Coming Autumn 2024 to select retailers worldwide.
Portable Keyboards for Work-on-the-go
Pro Keyboard Case collection
The Belkin Pro Keyboard case makes working from anywhere, easy. The backlit Bluetooth keyboard pairs to iPad to offer the ease of use of an external keyboard with the added defence of a protective cover. The premium faux leather exterior protects the device, while a soft, anti-slip interior protects the screen from scratches. It auto wakes/sleeps when opening/closing, and features a large, click-anywhere trackpad. Its long-lasting battery (between 460mAh – 600mAh) holds charge independently from iPad.
- Everyday Keyboard Case with Cradle for iPad Air 10.9" and iPad Pro 11" £99.99/ €109.99
- Pro Keyboard Case with Magnetic Stand for iPad Air 10.9" and iPad Pro 11"£139.99 / €149.99
- Pro Keyboard Case with Magnetic Stand for iPad Pro 12.9"£189.99 / €199.99
Availability: Available now at belkin.com/uk,belkin.com/de and Belkin EMEA retailers.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905171274/en/
Contacts
For Media Inquiries:
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom